The Filings Report

Guardant Health, Inc. Common Stock

GHNasdaqCIK 1576280Healthcare / Healthcare Providers & Servicesfiscal year ends December36 quarters since 2017

Revenue, Q2 FY2026
$335M
+44.3% on Q2 FY2025
Net income
−$120M
−20.3% on Q2 FY2025
Free cash flow
−$70M
−5.5% on Q2 FY2025
Diluted EPS
$-0.90
−12.5% on Q2 FY2025
Revenue, TTM
$1.2B
trailing four quarters
Net margin, TTM
-38.3%
net income −$453M
Free cash flow, TTM
−$241M
−$185M less $56M capex
Cash and equivalents
$1.1B
long-term debt $1.5B, Jun 30, 2026
Shares, 12-month change
+7.6%
134M shares, Jun 30, 2026
Buybacks, TTM
$0
0.0% of market value
Dividends, TTM
—
no yield
Market value
$24.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed July 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Guardant Health, Inc. Common Stock reported revenue of $335M, +44.3% on Q2 FY2025, and net loss of $120M (−20.3%). Operating margin was −38.5%. Free cash flow, operating cash flow less capital expenditures, was −$70M (−$58M less $12M). Diluted earnings per share were $-0.90.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 30, 2026.

Revenue and net incomeRevenueNet income
−$200M$0$200M$400MQ3'22, Revenue: $117MQ3'22, Net income: −$162MQ3'22Q4'22, Revenue: $127MQ4'22, Net income: −$140MQ4'22Q1'23, Revenue: $129MQ1'23, Net income: −$134MQ1'23Q2'23, Revenue: $137MQ2'23, Net income: −$73MQ2'23Q3'23, Revenue: $143MQ3'23, Net income: −$86MQ3'23Q4'23, Revenue: $155MQ4'23, Net income: −$187MQ4'23Q1'24, Revenue: $168MQ1'24, Net income: −$115MQ1'24Q2'24, Revenue: $177MQ2'24, Net income: −$103MQ2'24Q3'24, Revenue: $191MQ3'24, Net income: −$108MQ3'24Q4'24, Revenue: $202MQ4'24, Net income: −$111MQ4'24Q1'25, Revenue: $203MQ1'25, Net income: −$95MQ1'25Q2'25, Revenue: $232MQ2'25, Net income: −$100MQ2'25Q3'25, Revenue: $265MQ3'25, Net income: −$93MQ3'25Q4'25, Revenue: $281MQ4'25, Net income: −$128MQ4'25Q1'26, Revenue: $302MQ1'26, Net income: −$112MQ1'26Q2'26, Revenue: $335MQ2'26, Net income: −$120MQ2'26−$200M$0$200M$400MQ3'22, Revenue: $117MQ3'22, Net income: −$162MQ4'22, Revenue: $127MQ4'22, Net income: −$140MQ4'22Q1'23, Revenue: $129MQ1'23, Net income: −$134MQ2'23, Revenue: $137MQ2'23, Net income: −$73MQ2'23Q3'23, Revenue: $143MQ3'23, Net income: −$86MQ4'23, Revenue: $155MQ4'23, Net income: −$187MQ4'23Q1'24, Revenue: $168MQ1'24, Net income: −$115MQ2'24, Revenue: $177MQ2'24, Net income: −$103MQ2'24Q3'24, Revenue: $191MQ3'24, Net income: −$108MQ4'24, Revenue: $202MQ4'24, Net income: −$111MQ4'24Q1'25, Revenue: $203MQ1'25, Net income: −$95MQ2'25, Revenue: $232MQ2'25, Net income: −$100MQ2'25Q3'25, Revenue: $265MQ3'25, Net income: −$93MQ4'25, Revenue: $281MQ4'25, Net income: −$128MQ4'25Q1'26, Revenue: $302MQ1'26, Net income: −$112MQ2'26, Revenue: $335MQ2'26, Net income: −$120MQ2'26

Net income losses drawn in red.

Free cash flow
−$150M−$100M−$50M$0$50MQ3'22, Free cash flow: −$100MQ3'22Q4'22, Free cash flow: −$101MQ4'22Q1'23, Free cash flow: −$82MQ1'23Q2'23, Free cash flow: −$101MQ2'23Q3'23, Free cash flow: −$80MQ3'23Q4'23, Free cash flow: −$83MQ4'23Q1'24, Free cash flow: −$37MQ1'24Q2'24, Free cash flow: −$99MQ2'24Q3'24, Free cash flow: −$55MQ3'24Q4'24, Free cash flow: −$83MQ4'24Q1'25, Free cash flow: −$67MQ1'25Q2'25, Free cash flow: −$66MQ2'25Q3'25, Free cash flow: −$46MQ3'25Q4'25, Free cash flow: −$54MQ4'25Q1'26, Free cash flow: −$71MQ1'26Q2'26, Free cash flow: −$70MQ2'26−$150M−$100M−$50M$0$50MQ3'22, Free cash flow: −$100MQ4'22, Free cash flow: −$101MQ4'22Q1'23, Free cash flow: −$82MQ2'23, Free cash flow: −$101MQ2'23Q3'23, Free cash flow: −$80MQ4'23, Free cash flow: −$83MQ4'23Q1'24, Free cash flow: −$37MQ2'24, Free cash flow: −$99MQ2'24Q3'24, Free cash flow: −$55MQ4'24, Free cash flow: −$83MQ4'24Q1'25, Free cash flow: −$67MQ2'25, Free cash flow: −$66MQ2'25Q3'25, Free cash flow: −$46MQ4'25, Free cash flow: −$54MQ4'25Q1'26, Free cash flow: −$71MQ2'26, Free cash flow: −$70MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5B$2.0BQ3'22, Cash and equivalents: $158MQ3'22Q4'22, Cash and equivalents: $142MQ4'22Q1'23, Cash and equivalents: $224MQ1'23Q2'23, Cash and equivalents: $271MQ2'23Q3'23, Cash and equivalents: $457MQ3'23Q4'23, Cash and equivalents: $1.1BQ4'23Q1'24, Cash and equivalents: $1.0BQ1'24Q2'24, Cash and equivalents: $934MQ2'24Q3'24, Cash and equivalents: $585MQ3'24Q4'24, Cash and equivalents: $526MQ4'24, Long-term debt: $1.1BQ4'24Q1'25, Cash and equivalents: $699MQ1'25, Long-term debt: $1.1BQ1'25Q2'25, Cash and equivalents: $629MQ2'25, Long-term debt: $1.1BQ2'25Q3'25, Cash and equivalents: $580MQ3'25, Long-term debt: $1.1BQ3'25Q4'25, Cash and equivalents: $378MQ4'25, Long-term debt: $1.5BQ4'25Q1'26, Cash and equivalents: $989MQ1'26, Long-term debt: $1.5BQ1'26Q2'26, Cash and equivalents: $1.1BQ2'26, Long-term debt: $1.5BQ2'26$0$500M$1.0B$1.5B$2.0BQ3'22, Cash and equivalents: $158MQ4'22, Cash and equivalents: $142MQ4'22Q1'23, Cash and equivalents: $224MQ2'23, Cash and equivalents: $271MQ2'23Q3'23, Cash and equivalents: $457MQ4'23, Cash and equivalents: $1.1BQ4'23Q1'24, Cash and equivalents: $1.0BQ2'24, Cash and equivalents: $934MQ2'24Q3'24, Cash and equivalents: $585MQ4'24, Cash and equivalents: $526MQ4'24, Long-term debt: $1.1BQ4'24Q1'25, Cash and equivalents: $699MQ1'25, Long-term debt: $1.1BQ2'25, Cash and equivalents: $629MQ2'25, Long-term debt: $1.1BQ2'25Q3'25, Cash and equivalents: $580MQ3'25, Long-term debt: $1.1BQ4'25, Cash and equivalents: $378MQ4'25, Long-term debt: $1.5BQ4'25Q1'26, Cash and equivalents: $989MQ1'26, Long-term debt: $1.5BQ2'26, Cash and equivalents: $1.1BQ2'26, Long-term debt: $1.5BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Guardant Health, Inc. Common Stock income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue335302281265232203202191+44.3%
Cost of revenue116105999481757874+42.8%
Gross profit—————————
Research and development9791989087899487+10.4%
Selling, general and administrative6258615350475249+22.7%
Operating income(129)(121)(121)(99)(106)(111)(126)(117)−21.3%
Other income (expense)00(18)0085(3)+1332.0%
Pretax income(120)(112)(130)(93)(100)(95)(110)(108)−20.1%
Income tax00(2)00010+386.8%
Net income(120)(112)(128)(93)(100)(95)(111)(108)−20.3%
Diluted EPS ($)(0.90)(0.85)—(0.74)(0.80)(0.77)—(0.88)−12.5%
Diluted shares (millions)133131—125124124—123—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Guardant Health, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents1,053989378580629699526585+67.4%
Short-term investments0113823000314311—
Total current assets1,3651,3681,4668298839271,0551,227+54.5%
Total assets1,9121,9152,0141,2771,3321,3441,4861,539+43.6%
Total current liabilities339292303237238226226197+42.2%
Long-term debt1,5031,5031,5041,1151,1161,1161,143—+34.7%
Total liabilities2,1352,0962,1131,6311,6371,5951,6251,599+30.4%
Stockholders’ equity(223)(181)(99)(354)(305)(251)(140)(60)+27.0%
Shares outstanding (millions)134133131126125124123124—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Guardant Health, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow(58)(66)(26)(35)(60)(63)(65)(51)+4.2%
Capital expenditures126281064194+108.2%
Free cash flow (CFO − capex)(70)(71)(54)(46)(66)(67)(83)(55)−5.5%
Depreciation and amortization10910910101011−4.8%
Share repurchases000004500—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 19, 2026.

Income statement

Guardant Health, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Mar 19, 2019FY2017ended Dec 31, 2017filed Nov 19, 2018FY2016ended Dec 31, 2016filed Mar 19, 2019
Revenue982739564450374287214915025
Cost of revenue349290227———————
Gross profit——————————
Research and development36434836737426315086512611
Selling, general and administrative21118015616420719361363710
Operating income(437)(444)(565)(544)(411)(255)(82)(93)(77)(44)
Other income (expense)(10)(43)53(13)25405(1)0
Pretax income(418)(435)(479)(653)(384)(246)(70)(84)(83)(46)
Income tax(1)11100(2)000
Net income(416)(436)(479)(655)(385)—(76)(85)(83)(46)
Diluted EPS ($)(3.32)(3.56)(4.28)(6.41)(4.00)(2.60)(0.84)———
Diluted shares (millions)1251231121021019891———

Balance sheet

Guardant Health, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Mar 19, 2019FY2017ended Dec 31, 2017filed Nov 19, 2018FY2016ended Dec 31, 2016filed Mar 19, 2019
Cash and equivalents3785261,13414249283314314172—
Short-term investments82331435870441962380278149—
Total current assets1,4661,0551,3471,1921,1141,888597469243—
Total assets2,0141,4861,7861,6102,2042,272963587343—
Total current liabilities30322620619319567734720—
Long-term debt1,5041,143————————
Total liabilities2,1131,6251,6281,5501,5599161156234—
Stockholders’ equity(99)(140)159606451,29879848330980
Shares outstanding (millions)1311231221031021009486——

Cash flow statement

Guardant Health, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Mar 19, 2019FY2017ended Dec 31, 2017filed Nov 19, 2018FY2016ended Dec 31, 2016filed Mar 19, 2019
Operating cash flow(185)(240)(325)(309)(209)(104)(47)(72)(72)(37)
Capital expenditures483520777536192072
Free cash flow (CFO − capex)(233)(275)(345)(387)(284)(140)(66)(92)(79)(38)
Depreciation and amortization40424336221611754
Share repurchases4500——00070
Dividends paid——————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$31M
27 sales by 10 insiders; officers and directors $31M
Bought, twelve months
$78K
1 purchases by 1 insider; officers and directors $78K
Sold, twelve months
$169M
141 sales by 15 insiders; officers and directors $169M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 21, 2026Mignone RobertoDirectoroption exercise264$0.00—10,538Oct 22, 2026
Oct 17, 2026Hidalgo Medina ManuelDirectoroption exercise232$0.00—5,252Oct 19, 2026
Oct 16, 2026Tariq MusaDirectoropen-market sale10b5-1116$165.88$19K11,583Oct 19, 2026
Oct 15, 2026Tariq MusaDirectoroption exercise250$0.00—11,699Oct 19, 2026
Oct 14, 2026Azar Alex M IIDirectoropen-market sale10b5-169$159.89$11K893Oct 15, 2026
Oct 12, 2026Azar Alex M IIDirectoroption exercise137$0.00—962Oct 13, 2026
Oct 1, 2026Saia John G.Chief Legal Officeroption exercise974$0.00—39,965Oct 2, 2026
Oct 1, 2026Saia John G.Chief Legal Officeroption exercise1,668$0.00—41,633Oct 2, 2026
Oct 1, 2026Saia John G.Chief Legal Officeroption exercise2,925$0.00—44,558Oct 2, 2026
Oct 1, 2026Saia John G.Chief Legal Officeroption exercise1,496$0.00—46,054Oct 2, 2026
Oct 1, 2026Saia John G.Chief Legal Officertax withholding3,706$174.75$648K42,348Oct 2, 2026
Oct 1, 2026Monroe Terilyn J.Chief People Officeroption exercise2,659$0.00—25,638Oct 2, 2026
Oct 1, 2026Monroe Terilyn J.Chief People Officeroption exercise1,360$0.00—26,998Oct 2, 2026
Oct 1, 2026Monroe Terilyn J.Chief People Officertax withholding2,098$174.75$367K24,900Oct 2, 2026
Oct 1, 2026Kalia KumudChief Information Officeroption exercise1,607$0.00—41,401Oct 2, 2026
Oct 1, 2026Kalia KumudChief Information Officeroption exercise1,084$0.00—42,485Oct 2, 2026
Oct 1, 2026Kalia KumudChief Information Officeroption exercise1,995$0.00—44,480Oct 2, 2026
Oct 1, 2026Kalia KumudChief Information Officeroption exercise1,360$0.00—45,840Oct 2, 2026
Oct 1, 2026Kalia KumudChief Information Officertax withholding3,067$174.75$536K42,773Oct 2, 2026
Oct 1, 2026Freeman ChrisChief Commercial Officeroption exercise1,929$0.00—67,303Oct 2, 2026
Oct 1, 2026Freeman ChrisChief Commercial Officeroption exercise1,668$0.00—68,971Oct 2, 2026
Oct 1, 2026Freeman ChrisChief Commercial Officeroption exercise2,527$0.00—71,498Oct 2, 2026
Oct 1, 2026Freeman ChrisChief Commercial Officeroption exercise1,292$0.00—72,790Oct 2, 2026
Oct 1, 2026Freeman ChrisChief Commercial Officertax withholding3,143$174.75$549K69,647Oct 2, 2026
Oct 1, 2026Chudova DaryaChief Technology Officeroption exercise1,340$0.00—71,975Oct 2, 2026

Full insider history for Guardant Health, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held GH in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded GH by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$2M16,5000.00%trimmed −48.4%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
GUARDANT HEALTH, INC., CIK 1576280 on EDGAR
Extract generated
November 1, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/GH.json